PIK3CB and small cell lung carcinoma: The availability of clinical toxicology results from these FDA-approved PI3K inhibitors would facilitate the design of clinical plans pertaining to the use of PI3K inhibitors for the treatment of SCLC, particularly in terms of working dosages and adverse effects.